Periodontitis is far more than a dental nuisance. When the disease-causing bacteria that triggers gum inflammation enters the bloodstream, it has been linked to diabetes, cardiovascular disease, arthritis, rheumatic disease, inflammatory bowel disease, and even Alzheimer's. Yet conventional treatments have worked against the mouth's natural defenses.
Traditional mouthwashes and antiseptic rinses destroy the pathogens responsible for gum disease, but they also eliminate the beneficial bacteria that keep the mouth healthy. After treatment, the harmful species typically return faster than the good ones can recover, creating an imbalance that allows disease to resurface.
Researchers at the Fraunhofer Institute for Cell Therapy and Immunology in Germany identified a different approach. Instead of killing bacteria indiscriminately, they developed a compound that specifically blocks the growth of pathogens like Porphyromonas gingivalis, the primary culprit in periodontitis, while leaving the rest of the oral microbiome untouched.
"Rather than simply killing gingivitis pathogens, it inhibits their growth," explains Stephan Schilling, Head of the Fraunhofer IZI branch Molecular Drug Biochemistry and Therapy Development. "They are unable to exert their toxic effects, so beneficial bacteria can occupy niches that would otherwise be inaccessible to them."
The compound, called guanidinoethylbenzylamino imidazopyridine acetate, works by creating conditions where healthy microbes can thrive while disease-causing bacteria lose their foothold. This allows the mouth to naturally rebalance itself without the dysbiosis that plagues conventional treatments.
The discovery emerged from an EU-funded research project and was commercialized in 2018 when Periotrap Pharmaceuticals was founded in Halle. Transforming lab science into a functional toothpaste required solving practical challenges. The active ingredient needed to be safe for daily use, non-toxic, unable to enter the bloodstream, and incapable of staining teeth.
Fraunhofer researchers conducted extensive biochemical and structural studies to optimize the formulation. Their colleagues at the Fraunhofer Institute for Microstructure of Materials and Systems then tested how the product interacted with teeth and gums using scanning electron microscopy and chemical analysis to verify both safety and performance.
All work adhered to Good Laboratory Practice standards, ensuring the resulting toothpaste met strict regulatory requirements for medical-grade products. The final formula includes the active compound along with conventional toothpaste ingredients like abrasives and fluoride to prevent cavities.
"We didn't just develop a good toothpaste with a new ingredient," Schilling says. "We developed a high-quality oral care product of medical-grade standard."
The company has expanded beyond toothpaste. A gel designed for use after professional dental cleanings is already in production, and researchers are developing additional products including a mouthwash. Because the underlying disease mechanism is similar in animals, veterinary applications for dogs and cats are also being explored.
The oral microbiome contains more than 700 bacterial species. Only a handful cause periodontitis, but their effects ripple far beyond the mouth. By targeting just the troublemakers and letting the beneficial species flourish, this new generation of oral care products offers a fundamentally different path to preventing gum disease.
Author Jessica Williams: "Finally, a toothpaste that fights disease without nuking your mouth's natural defenses, and the science backs it up."
Comments